Skip to content

Livagen

Tetrapeptide bioregulator showing high activity in liver cells. Supports KEDA, liver, hepatic, chromatin remodeling and hepatic tissue function. Sequence: Lys-Glu-Asp-Ala.

Intelligence Profile

Research Papers

Research Papers Summary

The available research on Livagen consists primarily of small-scale studies published in Georgian medical journals, with limited evidence from peer-reviewed international publications. No clinical trials were identified in major trial registries.

Epigenetic and Genomic Studies

The most recent research (2023) investigated Livagen's effects on epigenetic modifications in aged chromatin, though specific study details and sample sizes were not provided in the available abstracts. A 2017 study examined peptide regulators in rodent models comparing long and short lifespan characteristics, but again lacked detailed methodology information.

Clinical Applications Research

Several studies explored Livagen's potential in various medical conditions:

  • Cardiovascular conditions: Two studies (2013, 2014) examined peptide bioregulators in patients with hypertrophic cardiomyopathy and their relatives, focusing on genomic regulation and chromosome activity markers
  • Cancer research: Studies investigated genomic parameters in ductal breast cancer patients (2017) and the effects on chromosome fragile sites in breast cancer patients compared to different age groups (2008)
  • Age-related conditions: A 2020 study examined polypeptide liver complex and tetrapeptide effects on physiological functions in normal aging and age-related pathology

Study Limitations

The available evidence has significant limitations:

  • Most studies appear to be small-scale laboratory or observational studies
  • Sample sizes are not clearly reported in the available abstracts
  • The majority of publications are in Georgian medical journals with limited international peer review
  • No randomized controlled trials were identified
  • Detailed methodology and statistical analyses are not available from the abstracts

Disclaimer: This synthesis is based solely on limited abstract information. The evidence base for Livagen remains preliminary, and individuals should consult healthcare providers before considering any peptide-based interventions.

Free account required

Research papers requires a free AXIFI account to access clinical data, safety profiles, and research papers.